Vanadium oxysulfate (VOSO4) reduced the low-grade systemic inflammation in type 2 diabetes mellitus (T2DM) through the reduction of both pro-inflammatory cytokines and adhesion molecules and increased adiponectin [21]. Here, ADIPOQ is linked to type 2 diabetes mellitus.